LYT-200 + venetoclax + decitabine

LYT-200 + venetoclax + decitabine is a **combination regimen** under clinical evaluation for relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS)[1][2][4][6]. - **LYT-200** is a fully human IgG4 monoclonal antibody targeting galectin-9, a protein that drives malignancy and suppresses antitumor immunity. By downregulating galectin-9, LYT-200 enhances activation of NK and T cells and promotes direct cytotoxicity in leukemic cells[1][2][5]. - **Venetoclax** is a small molecule BCL-2 inhibitor that induces apoptosis in leukemia cells by restoring programmed cell death pathways. - **Decitabine** is a hypomethylating agent (HMA) that acts as a DNA methyltransferase inhibitor, promoting anti-leukemic gene activation and cell differentiation. The combination aims to leverage LYT-200’s immune modulation and direct cytotoxic activity together with the apoptosis-inducing effect of venetoclax and the epigenetic activity of decitabine. Initial phase 1 trial results suggest this triplet regimen is well-tolerated, with encouraging signs of clinical benefit even in heavily pretreated and venetoclax-refractory populations[1][2][4][6].

Other names

LYT-200 + venetoclax + decitabine